AbbVie says multiple parties vying for assets related to Allergan deal approval - (Yahoo!Finance via NewsPoints Desk)

  • AbbVie says it has been negotiating with several parties interested in buying the two assets it intends to divest in order to secure approval to complete its $63-billion Allergan takeover, as reported by Yahoo!Finance.

  • The company plans to divest the experimental inflammatory bowel disease therapy brazikumab, as well as its exocrine pancreatic insufficiency treatment Zenpep.

  • The US Federal Trade Commission (FTC) had asked the companies for additional information in September that AbbVie said was not unexpected and that the companies were working through the agency's requests.

To read more NewsPoints articles, click here.